Introduction
Esophageal cancer (EC) is a complex disease characterized by progressive dysphagia and emaciation. Because of aging and unhealthy lifestyles (eg, low intake of fruit and vegetables, the rising prevalence of smoking and drinking), EC constitutes a burden worldwide. Esophageal squamous-cell carcinoma (ESCC) is the most common subtype of EC in China. 1, 2 The potential risk factors driving the high incidence of ESCC are not well understood. It is thought that poor nutritional status, insufficient fruit/ vegetables intake, smoking, and drinking beverages at very high temperatures may be involved in the development of ESCC, though these potential risk factors cannot explain the total etiology of ESCC. Nowadays, it is considered that genetic variants may influence the risk of ESCC.
PPARs comprise a group of nuclear transcription factors, which are classified into three subtypes: PPARα, PPARβ, and PPARγ. 3 PPARγ is also named PPARG. In humans, the PPARG gene is located on chromosome 3p25. PPARG interacts with the retinoid X receptor, constructs a dipolymer, and then regulates its target submit your manuscript | www.dovepress.com
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Qiu et al genes, which are involved in cellular differentiation and metabolism of carbohydrates and lipids. 4 Polymorphisms in the PPARG gene are assumed to influence the development of malignancies and metabolism-related diseases. Pro12Ala (rs1801282 C.G) and His449His (rs3856806 C.T) polymorphisms are the two most common single-nucleotide polymorphism (SNPs) in the PPARG gene. Recently, a case-control study was conducted to assess the relationship of PPARG rs3856806 C.T with susceptibility to EC. The results indicated that PPARG rs3856806 C.T might be associated with the risk of EC. 5 In addition, the association between PPARG rs1801282 C.G polymorphism and EC risk was unknown.
IGF2BP2 binds to the 5′UTR of IGF2 mRNA and affects its translation. 6 Barghash et al reported that IGF2BP2 expression correlated with poor survival in patients with esophageal adenocarcinoma and ESCC. 7 Case-control studies have indicated that IGF2BP2 rs4402960 G.T might be associated with the risk of breast cancer 8 and colorectal cancer. 9 In addition, it has been reported that IGF2BP2 rs1470579 A.C was associated with the risk of type 2 diabetes. 10, 11 However, the association between IGF2BP2 polymorphisms and EC risk was unclear.
The aim of this case-control study was to explore the potential relationship of genetic variations in PPARG and IGF2BP2 with risk of ESCC in the eastern Chinese Han population. PPARG rs1801282 C.G and rs3856806 C.T and IGF2BP2 rs1470579 A.C and rs4402960 G.T polymorphisms were selected and genotyped by SNPscan genotyping assays in 507 patients with ESCC and 1,496 controls.
Materials and methods subjects
A total of 507 patients pathologically confirmed for ESCC from the Affiliated People's Hospital of Jiangsu University and the Affiliated Union Hospital of Fujian Medical University (mean age 62.77±8.01 years) were recruited in our study. The noncancer controls consisted of 1,496 age-, sex-, and residence-matched healthy individuals (mean age 62.77 ±8.84 years) without any cancer history or autoimmune diseases. All participants were enrolled between August 2013 and December 2016. EDTA-anticoagulated peripheral blood was collected after written consent had been signed. A questionnaire was used to obtain participants' risk factors and demographic variables. A body-mass index (BMI) $24 kg/m 2 was accepted as the criterion of obesity and overweight. 12, 13 This study was approved by the institutional review boards of Jiangsu University (Zhenjiang, China) and Fujian Medical University (Fuzhou, China).
Dna extraction and genotyping
Genomic DNA was extracted from whole blood using a DNA kit (Promega, Madison, WI, USA). PPARG rs1801282 C.G and rs3856806 C.T and IGF2BP2 rs1470579 A.C and rs4402960 G.T genotypes were determined by double ligation and multiplex-fluorescence polymerase chain reaction (SNPscan; Genesky Biotechnologies, Shanghai, China).
14 For quality control, 80 samples (4%) were randomly selected from the 2,003 DNA samples and genotyped again by another technician. Genotypes of PPARG rs1801282 C.G and rs3856806 C.T and IGF2BP2 rs1470579 A.C and rs4402960 G.T polymorphisms were confirmed.
statistical analysis
Continuous variables (age, BMI, height, and weight) are expressed as means ± SD. Comparisons of these continuous variables between two groups were performed using Student's t-test. The χ 2 test was used to compare categorical variables (PPARG and IGF2BP2 genotypes, BMI, sex, age, and smoking status and alcohol use). We checked the deviations for HardyWeinberg equilibrium in normal controls with an Internetbased calculator (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). [15] [16] [17] [18] [19] [20] [21] Statistical significance was defined as P,0.05 (two-tailed). The relationships of PPARG rs1801282 C.G and rs3856806 C.T and IGF2BP2 rs1470579 A.C and rs4402960 G.T polymorphisms with ESCC susceptibility were determined by crude odds ratios (ORs) and 95% CIs. Adjusted for BMI, age, sex, alcohol use, and smoking status, multivariate linear regression was used to assess the potential association further among these polymorphisms and susceptibility to ESCC. SAS 9.4 software for Windows (SAS Institute, Cary, NC, USA) was used to analyze the data. SHEsis software (http://analysis. bio-x.cn/myanalysis.php; Bio-X, Shanghai, China) was used online to construct the haplotypes.
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Results
Baseline characteristics
Characteristics of 507 ESCC cases and 1,496 controls included in this case-control study are presented in Table 1 . ESCC cases and controls were well matched on age and sex, as shown by χ 2 tests (P=0.994 and P=0.406, respectively). As shown in Table 1 , significant differences were found on smoking status and alcohol use between cases and controls (P,0.001). The primary information for PPARG rs1801282 C.G and rs3856806 C.T and IGF2BP2 rs1470579 A.C and rs4402960 G.T SNPs is shown in 
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IGF2BP2 and PPARG polymorphisms and escc susceptibility quality-control testing were 100%. Minor allele frequency of PPARG rs1801282 C.G and rs3856806 C.T and IGF2BP2 rs1470579 A.C and rs4402960 G.T SNPs in controls was close to the minor allele-frequency data for Chinese (Table 2 ). In controls, the genotype frequencies for PPARG rs1801282 C.G and rs3856806 C.T polymorphisms were in HardyWeinberg equilibrium ( Table 2) . association of PPARG rs1801282 c.g and rs3856806 c.T and IGF2BP2 rs1470579 a.c and rs4402960 g.T polymorphisms with escc risk
The genotypes of PPARG rs1801282 C.G and rs3856806 C.T and IGF2BP2 rs1470579 A.C and rs4402960 G.T polymorphisms are summarized in Table 3 . In single-locus analyses, the genotype frequencies of PPARG rs3856806 C.T were 54.56% (CC), 39.09% (CT), and 6.35% (TT) in ESCC patients and 59.7% (CC), 36.13% (CT), and 4.16% (TT) in controls. When the PPARG rs3856806 CC homozygote genotype was used as the reference group, the PPARG rs3856806 CT genotype was correlated with a significantly increased risk of ESCC (CT vs CC, adjusted OR 1.28, 95% CI=1.02-1.6; P=0.033). When the PPARG rs3856806 CC homozygote genotype was used as the reference group, the PPARG rs3856806 TT genotype was correlated with a borderline significantly increased risk of ESCC (TT vs CC, adjusted OR 1.55, 95% CI=0.96-2.50; P=0.074). In the recessive model, when the PPARG rs3856806 CC/CT genotypes were used as the reference group, the PPARG rs3856806 TT homozygote genotype was not associated with susceptibility for ESCC (adjusted OR 1.41, 95% CI=0.88-2.26; P=0.153). In the dominant model, PPARG rs3856806 CT/TT genotypes were associated with an increased risk of ESCC compared with the PPARG rs3856806 CC genotype (adjusted OR 1.31, 95% CI=1.06-1.63; P=0.014) ( Table 3) . Logistic regression analyses showed that PPARG rs1801282 C.G and IGF2BP2 rs1470579 A.C, rs4402960 G.T polymorphisms were not correlated with the susceptibility for ESCC (Table 3) .
association of PPARG rs1801282 c.g and rs3856806 c.T and IGF2BP2 rs1470579 a.c and rs4402960 g.T polymorphisms with escc risk in different stratification groups
To determine the potential effects of PPARG rs1801282 C.G genotypes on ESCC risk in different subgroups according to BMI, age, sex, and smoking and drinking status, we carried out stratified analyses (Table 4 ). In the never-smoking subgroup, after adjustment for sex, age, BMI, and alcohol use, we found that the PPARG rs1801282 C.G polymorphism increased ESCC risk in two genetic models (CG vs CC, Table 4 ]). Table 5 shows genotype frequencies of PPARG rs3856806 C.T in different subgroups. Significantly increased susceptibility to ESCC associated with the PPARG rs3856806 C.T polymorphism was found among several subgroups ( 
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IGF2BP2 and PPARG polymorphisms and escc susceptibility [ Table 5] ). In addition, there was no significant risk of ESCC correlated with the IGF2BP2 rs1470579 A.C and rs4402960 G.T polymorphisms evident among any subgroup (data not shown).
snP haplotypes
Using the SHEsis software, 22 we constructed eight haplotypes (Table 6 ). There were significant differences in the CGCC haplotype of the order rs1470579 A.C, rs4402960 G.T, rs1801282 C.G and rs3856806 C.T polymorphism distribution among ESCC cases and the control subjects (OR 2.23, 95% CI=1.09-4.59; P=0.025 [ Table 6 ]).
Discussion
In this case-control study, we explored the associations between the PPARG rs1801282 C.G and rs3856806 C.T and IGF2BP2 rs1470579 A.C and rs4402960 G.T SNPs and risk of ESCC in the eastern Chinese Han population. Multivariable logistic analysis suggested that PPARG rs3856806 C.T might be associated with an increased risk of ESCC. In different stratified analyses, there were significant associations between this polymorphism and risk of ESCC in the female, never-smoking, drinking, and never-drinking subgroups. In addition, we also found that PPARG rs1801282 C.G increased ESCC risk in the never-smoking subgroup. To the best of our knowledge, this is the first study to identify a potential association between PPARG rs1801282 C.G and rs3856806 C.T polymorphisms and increased risk of ESCC in Asians.
PPARG is a member of the nuclear hormone-receptor superfamily and may possess anti-inflammatory properties. 25 PPARG also plays an important role in cell proliferation/ differentiation, which affects the development and progression of cancer. 26, 27 The PPARG rs1801282 C.G polymorphism is located in the exon B region of the PPARG gene. Deeb et al reported that this SNP was associated with decreased transactivation activity and lower BMI and promoted insulin sensitivity. 28 A recent meta-analysis suggested that PPARG rs1801282 C.G polymorphism is a candidate for susceptibility to Asians. 29 The association between PPARG rs1801282 C.G and risk of ESCC has not been studied before. In this study, we found that the PPARG rs1801282 CG genotype was more frequent in ESCC patients in the never-smoking subgroup, which was in accordance with the results of the meta-analysis just mentioned. The function of the PPARG rs1801282 C.G SNP remains to be investigated in ESCC patients. There was a difference in genotype distribution of the PPARG rs3856806 C.T polymorphism between ESCC patients and controls. The PPARG rs3856806 CT and TT/CT genotypes were more frequent in ESCC patients compared with healthy controls, suggesting that the PPARG rs3856806 TT/CT and CT genotypes might contribute to the development of ESCC. The PPARG rs3856806 C.T polymorphism is located in the exon of the PPARG gene. It is difficult to illustrate the exact function of a synonymous SNP. It is proposed that PPARG rs3856806 C→T substitution may disrupt the splice site, 30 and then affect the expression of PPARG. A meta-analysis suggested that PPARG rs3856806 C.T is marginally associated with cancer susceptibility, 31 and our results were similar.
In the present investigation, we constructed eight haplotypes to study inherited patterns. We found that the C rs1470579 G rs4402960 C rs1801282 C rs3856806 haplotype was associated 
5531
IGF2BP2 and PPARG polymorphisms and escc susceptibility with susceptibility for ESCC. Comparing the CGCC with the AGCC haplotype in the order of rs1470579 A.C, rs4402960 G.T, rs1801282 C.G, and rs3856806 C.T polymorphisms, we found that A→C variation in the rs1470579 A.C locus led to susceptibility of the haplotype to ESCC. Several casecontrol studies have reported that IGF2BP2 rs1470579 A.C was associated with type 2 diabetes mellitus. 11, [32] [33] [34] However, a potential association between IGF2BP2 rs1470579 A.C polymorphism and ESCC risk was not found in our casecontrol study. In the future, more case-control studies with large samples and detailed risk factors should be carried out to confirm or refute our findings.
There were some limitations in our study. Firstly, this case-control study was limited by the moderate sample size of ESCC patients, which might lead to suboptimal power to identify true associations in the stratified analyses. Secondly, the controls were recruited from two local hospitals, and might not represent the general Chinese population well; this possible bias should not be ignored. Thirdly, only some functional SNPs in the PPARG and IGF2BP2 genes were selected. The relationship of PPARG and IGF2BP2 variants was not fully explored. In the future, a fine-mapping study should be conducted. Fourthly, detailed information on metastasis and survival of ESCC was not available at the time of research, which restricted further analysis on the potential role of PPARG and IGF2BP2 variants in ESCC progression and prognosis. Finally, for lack of some environmental risk factors, such as lifestyle and intake of fruit/vegetables, the interaction of gene variants with environmental risk factors was not considered.
Conclusion
Our findings highlight that PPARG rs1801282 C.G and rs3856806 C.T polymorphisms are candidates for susceptibility to ESCC in the eastern Chinese Han population. A fine-mapping study is required to confirm these preliminary findings.
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